Insufficient scRNA-seq data for expression of NAA80 at single-cell level.
Insufficient scRNA-seq data for expression of NAA80 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 876.08 | 180 / 180 | 100% | 18.19 | 430 / 430 |
esophagus | 100% | 646.52 | 1443 / 1445 | 100% | 10.04 | 183 / 183 |
thymus | 100% | 813.27 | 653 / 653 | 100% | 17.07 | 604 / 605 |
skin | 100% | 935.57 | 1809 / 1809 | 100% | 14.14 | 471 / 472 |
prostate | 100% | 1021.48 | 245 / 245 | 99% | 16.85 | 499 / 502 |
uterus | 100% | 890.59 | 170 / 170 | 99% | 11.50 | 456 / 459 |
intestine | 100% | 625.93 | 964 / 966 | 99% | 13.12 | 524 / 527 |
stomach | 100% | 673.14 | 359 / 359 | 99% | 11.65 | 283 / 286 |
brain | 99% | 826.48 | 2606 / 2642 | 100% | 16.86 | 705 / 705 |
breast | 100% | 784.41 | 459 / 459 | 98% | 12.46 | 1099 / 1118 |
adrenal gland | 100% | 580.51 | 257 / 258 | 98% | 12.33 | 226 / 230 |
lung | 100% | 827.76 | 576 / 578 | 98% | 9.86 | 1134 / 1155 |
bladder | 100% | 696.81 | 21 / 21 | 98% | 12.62 | 493 / 504 |
kidney | 100% | 668.99 | 89 / 89 | 98% | 9.35 | 880 / 901 |
pancreas | 99% | 414.16 | 325 / 328 | 98% | 12.23 | 174 / 178 |
liver | 95% | 367.25 | 215 / 226 | 99% | 10.58 | 400 / 406 |
eye | 0% | 0 | 0 / 0 | 100% | 13.20 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 14.46 | 29 / 29 |
spleen | 100% | 832.48 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 8.92 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 20.44 | 1 / 1 |
adipose | 100% | 670.29 | 1203 / 1204 | 0% | 0 | 0 / 0 |
muscle | 100% | 567.28 | 802 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 671.97 | 1332 / 1335 | 0% | 0 | 0 / 0 |
heart | 99% | 504.77 | 850 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 93% | 473.02 | 861 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0017190 | Biological process | N-terminal peptidyl-aspartic acid acetylation |
GO_0006473 | Biological process | protein acetylation |
GO_0030047 | Biological process | actin modification |
GO_0018002 | Biological process | N-terminal peptidyl-glutamic acid acetylation |
GO_0008064 | Biological process | regulation of actin polymerization or depolymerization |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_1905502 | Molecular function | acetyl-CoA binding |
GO_0008080 | Molecular function | N-acetyltransferase activity |
GO_0004596 | Molecular function | peptide alpha-N-acetyltransferase activity |
Gene name | NAA80 |
Protein name | N-alpha-acetyltransferase 80 (HsNAAA80) (EC 2.3.1.-) (N-acetyltransferase 6) (Protein fusion-2) (Protein fus-2) N-alpha-acetyltransferase 80, NatH catalytic subunit |
Synonyms | FUS2 NAT6 |
Description | FUNCTION: N-alpha-acetyltransferase that specifically mediates the acetylation of the acidic amino terminus of processed forms of beta- and gamma-actin (ACTB and ACTG, respectively) . N-terminal acetylation of processed beta- and gamma-actin regulates actin filament depolymerization and elongation . In vivo, preferentially displays N-terminal acetyltransferase activity towards acid N-terminal sequences starting with Asp-Asp-Asp and Glu-Glu-Glu . In vitro, shows high activity towards Met-Asp-Glu-Leu and Met-Asp-Asp-Asp . May act as a tumor suppressor . . |
Accessions | C9JL88 ENST00000443094.3 [Q93015-1] Q93015 ENST00000442620.5 ENST00000450489.1 C9J451 A0A1D5RMQ1 ENST00000417393.1 [Q93015-1] ENST00000443842.1 [Q93015-1] ENST00000354862.4 [Q93015-2] ENST00000452674.1 |